JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...
The extraordinary life of JP Morgan’s librarian Belle da Costa Greene
A New York exhibition pays homage to a Black woman who passed as white and assembled the financier’s private collection ...
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results
(NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for ...